StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Scribe Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.62–
Q2 FY2025Jun 30, 2025-$4.08–

More Scribe Therapeutics figures

See a number that looks wrong?